• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Fractyl Laboratories

Fractyl Health touts preliminary data from diabetes reversal study

January 20, 2022 By Sean Whooley

Fractyl Health this week announced encouraging interim feasibility data from its diabetes reversal technology study. Lexington, Massachusetts–based Fractyl’s Revita-T2Di long-term open-label cohort assessed eight patients followed through at least four weeks having been treated. The company’s Revita system resurfaces the upper intestine lining (duodenal mucosa) to treat metabolic disease in patients with insulin-treated type 2 diabetes. […]

Filed Under: Clinical Trials, Diabetes, Endoscopic, Featured Tagged With: Fractyl Health, Fractyl Laboratories

FDA authorizes expansion of Fractyl’s pivotal clinical trial for diabetes reversal tech

November 30, 2021 By Sean Whooley

Fractyl Health announced today that the FDA gave authorization to expand the Revitalize-1 pivotal clinical study of its Revita DMR system. Lexington, Massachusetts-based Fractyl Health (formerly Fractyl Laboratories) can now increase the sample size of the Revitalize-1 trial (formerly Revita-T2Di trial) from 288 to 420. Get the full story at our sister site, Drug Delivery Business […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: FDA, Fractyl Health, Fractyl Laboratories

Fractyl activates 10th clinical site in diabetes reversal tech trial

September 1, 2021 By Sean Whooley

Fractyl Health announced today that it activated the 10th clinical site in its pivotal REVITA-T2Di trial in the U.S. and Europe. Lexington, Mass.-based Fractyl’s trial is enrolling patients with type 2 diabetes who are currently on insulin therapy at sites in New Jersey, Louisiana, Texas, Massachusetts and New York to add to the initial U.S. site […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations Tagged With: Fractyl, Fractyl Health, Fractyl Laboratories

Fractyl raises $100M for diabetes reversal tech, renamed as Fractyl Health

June 16, 2021 By Sean Whooley

Fractyl Labs today announced the closing of a $100 million Series F financing round in addition to a name change to Fractyl Health. Lexington, Mass.–based Fractyl Health received contributions to the round from new investors Maverick Capital, M28 Capital and Population Health Partners, while other new and existing investors participated, too. Get the full story at […]

Filed Under: Business/Financial News, Diabetes, Featured, Funding Roundup Tagged With: Fractyl Health, Fractyl Laboratories

MedTech 100 roundup: More growth ahead?

May 24, 2021 By Sean Whooley

A turgid month for the medtech industry might be drifting into the past after the past week indicated a slight turnaround as summer nears. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week at 107.74 points, marking a 1.4% rise from the 106.22-point mark set one […]

Filed Under: Business/Financial News, Funding Roundup, Mergers & Acquisitions, Wall Street Beat Tagged With: BD, coronavirus, COVID-19, Cue Health, DarioHealth Corp, DeviceTalks Weekly, Fractyl Laboratories, Giiant Pharma, Google, MedTech 100 Index, Memic Innovative Surgery, Teleflex

How Fractyl Labs is ‘reversing’ type 2 diabetes to reduce or eliminate insulin injections

May 21, 2021 By Sean Whooley

Fractyl Labs CEO Harith Rajagopalan envisions a scenario in which those with type 2 diabetes don’t have to rely on insulin injections. Insulin has long been a staple of treatment for type 2 diabetes patients who need to manage their blood sugar levels, but Rajagopalan’s aim is to go beyond that temporary fix. Trained as […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: Fractyl Laboratories

FDA grants breakthrough nod for Fractyl’s type 2 diabetes treatment

April 27, 2021 By Sean Whooley

Fractyl Laboratories announced today that it received FDA breakthrough device designation for its Revita DMR type 2 diabetes treatment. Lexington, Mass.-based Fractyl’s Revita DMR treatment is an outpatient endoscopic procedure designed to resurface the upper intestine lining (duodenal mucosa) in metabolic disease for patients with insulin-treated type 2 diabetes. Preliminary clinical findings suggest that the treatment […]

Filed Under: Clinical Trials, Diabetes, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: FDA, Fractyl Laboratories

Fractyl enrolls first patient in Revita DMR treatment for Type 2 diabetes

March 22, 2021 By Sean Whooley

Fractyl Laboratories announced today that it enrolled the first patient in the trial for its Revita DMR Type 2 diabetes treatment. The Revita-T2Di trial will evaluate a single Revita DMR treatment to allow patients currently on insulin therapy but with inadequate glycemic control to achieve durable insulin-free glycemic control. The company will seek to use […]

Filed Under: Clinical Trials, Diabetes Tagged With: Fractyl Laboratories

MedTech 100 roundup: Stocks were practically unchanged last week

August 24, 2020 By Sean Whooley

Despite plenty of ups and downs coming in the stock market for the medtech industry, there was hardly any movement from week to week. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.6 points at the end of last week (Aug. 21). Overall, medtech stocks saw […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Initial Public Offering (IPO), Mergers & Acquisitions, Research & Development, Wall Street Beat Tagged With: Bayer, Cala Health, cochlear, conformis, CureVac, Fractyl Laboratories, Johnson and Johnson, momentapharmaceuticals, Principia Biopharma, S&P, Sanofi, Stryker, Teva Pharmaceuticals

DTW Podcast: Can Fractyl Labs and Cala Health go where only drugs have gone before?

August 21, 2020 By Tom Salemi

In this week’s DeviceTalks Weekly podcast, co-costs Tom Salemi and Chris Newmarker walk through this week’s “Newmarker’s Newsmakers,” the Top Five #medtech stories of the week with news coming from CureVac, Avail Medsystems, ClearMask, Thermo Fisher and Bayer. We also hear from CEO Harith Rajagopalan, MD and CFO Lisa Davidson of Fractyl Laboratories, which is […]

Filed Under: Bioelectronic Medicine, Biotech, Device Talks Podcasts, Diabetes, Featured, Initial Public Offering (IPO) Tagged With: Avail Medsystems, Bayer, Cala Health, ClearMask, CureVac, Fractyl Laboratories, Thermo Fisher Scientific

Fractyl adds $55M Series E for Type 2 diabetes pivotal trial

August 9, 2020 By Tom Salemi

Fractyl Laboratories secured $55 million for a Series E financing to continue funding a pivotal clinical trial of its potential non-drug, non-surgical treatment for Type 2 diabetes, according to the company. The capital will go toward the Lexington, Mass-based start up’s Revita T2Di pivotal clinical trial of Revita DMR (duodenal mucosal resurfacing). Revita is measuring […]

Filed Under: Business/Financial News, Diabetes, Endoscopic, Featured, Funding Roundup Tagged With: Fractyl Laboratories

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy